Capmatinib Market Price and Purchasing Options in 2024

Capmatinib (Capmatinib) is a revolutionary oral small molecule drug that can effectively inhibit the activity of mesenchymal-epithelial transition (MET) factor tyrosine kinase receptors and block signaling pathways closely related to cell proliferation, migration and invasion through competitive binding with hepatocyte growth factor (HGF).

In 2020, capmatinib was approved in the United States, becoming the first tumor treatment drug for adult patients with non-small cell lung cancer causing MET exon 14 skipping mutations. Meanwhile, its efficacy in other forms of MET-mutant cancer is also being evaluated. It is marketed under the trade name Tabrecta and is available in 150 mg and 200 mg tablet strengths.

Although the original drug of capmatinib has not yet been launched in the domestic market, this innovative drug is already available in Hong Kong. In Hong Kong, a box containing 60 tablets of 200 mg medicine costs more than 30,000 yuan, and this price will fluctuate with changes in the exchange rate.

In addition, overseas markets also provide purchase options for capmatinib. For example, in the European market, each box contains 120 tablets of 200 mg medicine, and the price even exceeds RMB 50,000. This price will also be affected by exchange rate changes.

More reasonably priced generic drug options also exist in overseas markets. These generic drugs are highly similar to the original drugs in terms of their active ingredients. For example, a medicine produced in Laos contains 56 tablets per box and has a specification of 200 mg. The price is only more than 3,000 yuan. Although this price may also fluctuate due to the impact of exchange rates, compared with the original drug, its price has been significantly reduced, providing the possibility of treatment for more patients.